Skip to main content

Scopolamine Transdermal System Shortage

Last Updated: June 9, 2025
Status: Current

Products Affected - Description
    • Transderm Scop transdermal system, Baxter, 1.5 mg (1 mg/3 days), 10 count, NDC 10019-0553-03
    • Transderm Scop transdermal system, Baxter, 1.5 mg (1 mg/3 days), 24 count, NDC 10019-0553-04
    • Scopolamine transdermal system, Teva, 1.3 mg (1 mg/3 days), 4 count, NDC 00591-2258-04
    • Scopolamine transdermal system, Teva, 1.3 mg (1 mg/3 days), 10 count, NDC 00591-2258-79
    • Scopolamine transdermal system, Teva, 1.3 mg (1 mg/3 days), 24 count, NDC 00591-2258-23
Reason for the Shortage
    • Baxter did not provide a reason for the shortage of Transderm Scop.
    • Ingenus has scopolamine transdermal patches available.
    • Padagis has scopolamine transdermal patches available.
    • Rhodes has scopolamine transdermal patches available.
    • Teva did not provide a reason for the shortage.
    • Viatris has scopolamine transdermal patches available.
    • Zydus has scopolamine transdermal patches available.
Available Products
    • Scopolamine transdermal system, Ingenus Pharmaceuticals, 1.3 mg (1 mg/3 days), 4 count, NDC 50742-0505-04
    • Scopolamine transdermal system, Ingenus Pharmaceuticals, 1.3 mg (1 mg/3 days), 10 count, NDC 50742-0505-10
    • Scopolamine transdermal system, Ingenus Pharmaceuticals, 1.3 mg (1 mg/3 days), 24 count, NDC 50742-0505-24
    • Scopolamine transdermal system, Mylan (Viatris), 1.3 mg (1 mg/3 days), 4 count, NDC 00378-6470-99
    • Scopolamine transdermal system, Mylan (Viatris), 1.3 mg (1 mg/3 days), 10 count, NDC 00378-6470-97
    • Scopolamine transdermal system, Mylan (Viatris), 1.3 mg (1 mg/3 days), 24 count, NDC 00378-6470-44
    • Scopolamine transdermal system, Padagis, 1.3 mg (1 mg/3 days), 4 count, NDC 45802-0580-84
    • Scopolamine transdermal system, Padagis, 1.3 mg (1 mg/3 days), 10 count, NDC 45802-0580-46
    • Scopolamine transdermal system, Padagis, 1.3 mg (1 mg/3 days), 24 count, NDC 45802-0580-62
    • Scopolamine transdermal system, Rhodes, 1.3 mg (1 mg/3 days), 4 count, NDC 42858-0150-40
    • Scopolamine transdermal system, Rhodes, 1.3 mg (1 mg/3 days), 10 count, NDC 42858-0150-14
    • Scopolamine transdermal system, Rhodes, 1.3 mg (1 mg/3 days), 24 count, NDC 42858-0150-70
    • Scopolamine transdermal system, Zydus, 1.3 mg (1 mg/3 days), 4 count, NDC 70710-1846-04
    • Scopolamine transdermal system, Zydus, 1.3 mg (1 mg/3 days), 10 count, NDC 70710-1846-02
    • Scopolamine transdermal system, Zydus, 1.3 mg (1 mg/3 days), 24 count, NDC 70710-1846-07

Estimated Resupply Dates

    • Baxter has Transderm Scop 1.3 mg patches on back order and the company cannot estimate a release date.
    • Teva has scopolamine 1.3 mg patches in 4 count on back order and the company estimates a release date in early- to mid-July 2025. The 10 count and 24 count are also on back order and the company estimates a release date in late-October 2025.

Updated

Created June 9, 2025 by Leslie Jensen, PharmD, Drug Information Specialist. © 2025, Drug Information Service, University of Utah, Salt Lake City, UT.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer